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Abstract
Identification of recurrent tumour-specific chromosomal translocations and novel fusion oncogenes has
important diagnostic, therapeutic and prognostic implications. Over the past decade, fluorescence in situ
hybridization (FISH) analysis of tumour samples has been one of the most rapidly growing areas in genomic
medicine and surgical pathology practice. Unlike traditional cytogenetics, FISH affords a rapid analysis of
formalin-fixed, paraffin-embedded cells within a routine pathology practice workflow. As more diagnostic and
treatment decisions are based on results of FISH, demand for the technology will become more widespread.
Common FISH-detected alterations are chromosome deletions, gains, translocations, amplifications and polys-
omy. These chromosome alterations may have diagnostic and therapeutic implications for many tumour types.
Integrating genomic testing into cancer treatment decisions poses many technical challenges, but rapid pro-
gress is being made to overcome these challenges in precision medicine. FISH assessment of chromosomal
changes relevant to differential diagnosis and cancer treatment decisions has become an important tool for
the surgical pathologist. The aim of this review is to provide a theoretical and practical survey of FISH
detected translocations with a focus on strategies for clinical application in surgical pathology practice.
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Introduction
In the late 1960s, in situ hybridization was first per-
formed with radioisotope-labelled probes followed by
autoradiography [1–3]. Fluorescence-labelled probe
technology started in the early 1980s with RNA
probes that were directly labelled with fluorophores
complementary to specific DNA sequences. Advan-
ces in fluorescence microscopy and digital imaging,
as well as widespread availability of genomic and
bioinformatic resources, have greatly improved the
resolution, sensitivity, specificity, and accessibility of
fluorescence in situ hybridization (FISH).
Interphase FISH, hereinafter simply referred to as
FISH, is the usual clinical application of this diagnos-
tic tool [4]. FISH involves the use of fluorescence
labelled fragments of DNA (probes) binding to
interphase chromosomes of cytology specimens or par-
affin embedded tissue sections. Common FISH-
detected alterations are chromosome deletions, gains,
translocations, amplifications and polysomy. These
chromosome alterations may have diagnostic and ther-
apeutic implications for many tumour types [5,6]. Inte-
grating precise genomic testing into cancer treatment
decisions poses technical challenges, but rapid pro-
gress is being made in overcoming these difficulties.
This review focuses on FISH based detection of trans-
locations applicable to surgical pathology.
Chromosomal translocations: an overview
Chromosomal translocation refers to a chromosome
rearrangement involving non-homologous chromosome
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pairs. Translocations can be balanced, without net gain
or loss of material, or unbalanced, with gain or loss of
genetic loci. Translocation often creates fusion genes
when two otherwise separated chromosome parts join
[7–9]. These fusion genes may behave as a hybrid chi-
meric oncogene, inducing tumorigenesis by gene over-
expression, or they may interrupt an important control
region, causing unresponsiveness to regulatory control
factors. For example, receptor tyrosine kinase gain of
function fusion oncogene is a mechanism whereby
mesenchymal cells may be transformed into sarcomas.
Constitutive activation of the insulin family kinase
ALK results from unregulated dimerization of the
fusion gene protein containing the active anaplastic
lymphoma kinase (ALK) kinase domain. This mecha-
nism underlies about half of inflammatory myofibro-
blastic tumours. Most Ewing sarcoma cases result
from EWSR1-FLI1 gene fusion deregulating the ETS
transcription factor FLI1, leading to aberrant expres-
sion of Ewing sarcoma transforming genes. The patho-
gnomonic fusion protein of dermatofibrosarcoma
protuberans (DFSP) is PDGFB-COL1A1. This amalga-
mation of the essential fibroblast collagen gene
(COL1A1) with the angiogenic growth factor gene
(PDGFB) leads to increased growth factor release. An
overabundance of growth factor results in overstimula-
tion of receptor tyrosine kinase PDGFR, activating not
only endothelial cells but also fibroblasts and inflam-
matory cells [10].
Translocations may involve two or more different
chromosomes or may exchange information between
regions in the same chromosome. Intra-chromosomal
rearrangement may cause transposition of the
involved loci with or without centromere involve-
ment. Chromosome rearrangement, whether intra-
chromosomal or between chromosomes, invariably
leads to a neoteric juxtaposition of previously unre-
lated gene elements into a new fusion gene that may
or may not be transcribed. Fusion gene detection,
therefore, is at the heart of FISH diagnostic testing.
Chromosomal translocation is detectable by several
methods, including FISH, metaphase karyotyping,
microarray comparative genomic hybridization, SNP-
array and next generation sequencing [10–20]. Most
chromosomal translocations are detectable by FISH,
either by split-apart (Figure 1) or fusion probes (Fig-
ure 2). To be a reliable diagnostic tool, the probe
sets must reproducibly show either an increase or a
decrease in the optical distance between probe sig-
nals. Some translocations, especially those involving
intra-chromosomal inversion or deletion, have a rela-
tively short physical distance between the fusion part-
ners after translocation. These small distances cannot
reliably be resolved at the light microscopic level. In
this scenario, a PCR-based method or RNA sequenc-
ing (RNA-Seq) is favoured. RNA-seq, a next genera-
tion sequencing technique, can detect both known
and novel gene fusion events and allows RNA analy-
sis through cDNA sequencing at a comprehensive
genome-wide scale. It can detect both cryptic intra-
chromosomal rearrangements and fusion products
with uncharacterized fusion partners [14,21–26].
Chromosomal translocations mainly associated
with sarcomas
About 30% of sarcomas have well documented spe-
cific translocations, and the percentage continues to
grow. With some exceptions, sarcoma translocations
form fusion genes with the 50 gene segment contrib-
uting a strong promoter and overexpression of the 30
proto-oncogene segment by transactivation. Recurrent
gene fusions in soft tissue sarcomas tend to occur in
tumours sharing similar morphological characteristics
[27]. Roughly half of the sarcoma-associated fusion
genes contain a member of the TET gene family,
including FUS, Ewing sarcoma breakpoint region 1
(EWSR1) is the promoter and TAF15 is the proto-
oncogene partner. Most fusion genes are strongly
associated with a particular tumour type, potentially
making them ideal molecular diagnostic markers
[10,27–29]. Some fusion proteins are actual or poten-
tial therapeutic targets, making the detection of
fusion gene products valuable both for diagnostic and
for therapeutic purposes.
More than 400 recurring translocations have been
found in soft tissue sarcomas. The challenge now is
to identify which of these recurring translocations
truly have diagnostic, mechanistic, or therapeutic
meaning for the associated sarcomas. Over 30 sub-
types of mesenchymal tumour can be confirmed by
FISH analysis based on tumour-specific chimeric
fusion sequences [28]. FISH-identifiable sarcomas
include many common entities: Ewing sarcoma/primi-
tive neuroectodermal tumour, synovial sarcoma, lipo-
sarcoma, round cell Ewing-like sarcoma, pulmonary
myxoid sarcoma, inflammatory myofibroblastic tumour
and others (Table 1).
Ewing sarcoma
Ewing sarcomas are composed of small round blue
cells with highly malignant behaviour, usually affect-
ing bone and extraosseous tissues of children and
young adults. There is a specific balanced chromo-
somal rearrangement in most Ewing sarcomas,
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providing a valuable tool for diagnosis. The fusion
partners of EWSR1 belong to several gene families,
mainly encoding transcription factors. These proteins
join the amino terminal of the EWSR1 gene with the
carboxy terminal of an ETS gene family member.
This fusion not only abrogates the RNA splicing
function of EWSR1 but also removes essential trans-
activating control regions of the ETS gene partner.
As many as 90% of the translocations involve the
EWSR1 gene in the form of t(11;22)(q24;q12) trans-
location, which juxtaposes EWSR1 at 22q12 with the
FLI1 gene on chromosome 11q24 [30].
The fusion gene encodes a protein containing the
upstream amino-terminal domain of EWSR1 and the
downstream carboxy-terminal region of FLI1. This
fusion protein uniquely functions in controlling cell
growth and regulating the transcription of down-
stream genes responsible for uncontrolled cell divi-
sion, and survival in the face of otherwise lethal
additional mutations. The ERG translocation,
t(21;22)(q22;12), resulting in EWSR1-ERG fusion,
represents only 10% of all Ewing sarcomas. The
functional consequences of these variant fusion pro-
teins are similar to those of the more common
EWSR1-FLI1 fusion. One study suggested a better
outcome for patients with localized tumours express-
ing the most common t(11;22) transcript (EWSR1
exon 7 fused to FLI1 exon 6), but limited prognostic
Figure 1. Break-apart probe design for translocations with multiple fusion partners. A break-apart probe set is composed of two
probes specific for loci physically close to each other on the chromosome in their wild type configuration. The wild type signal pat-
tern shows two pairs of closely approximated or fused signals (A). When translocation occurs involving a breakpoint between the two
probe sites, the originally juxtaposed loci (fusion signals) split apart (B). The beauty of this design is that it detects chromosomal
translocation regardless of the fusion partner involved. However, the break-apart probe only identifies the breaking away of a gene
fragment from its original location. It does not determine which chromosome receives the fragment or which genes may serve as
fusion partners in the new location.
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data is currently available for the less common fusion
types [31].
Myxoid liposarcoma
The diagnosis of myxoid liposarcoma may be
challenging by histology alone, especially on
small biopsy tissues, since a variety of soft tissue
tumours with myxoid change may mimic myxoid
liposarcoma. Myxoid liposarcoma represents about
10% of all adult sarcomas and approximately 33%
of all liposarcomas. Chromosomal translocations
t(12,16)(q13;p11) and t(12;22)(q13;q12), rendering
gene fusions of DNA-damage inducible transcript 3
(DDIT3) with FUS or EWSR1, respectively, are
characteristic of myxoid liposarcoma; one of these
Figure 2. Fusion design for translocation between specific partners. A fusion probe set contains two locus-specific probes labelled
with different colours targeting the genes known to fuse in certain tumours or diseases. The fusion probes identify chromosomal loci
far from each other either on the same chromosome or on different chromosomes. The wild type configuration shows two separated
signals resulting from physically separated chromosome loci (A). When fusion occurs, the two probes move to a closely approximated
position (fusion signal, B). This provides direct evidence of a gene fusion with definitive fusion partners identified.
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Table 1. Chromosome alterations in mesenchymal and uncertain derivation solid tumors
Tumor Type Chromosomal Translocation Genes Involved Freqency (%)
Adipocytic tumor
Chondroid lipoma t(11;16)(q13;p13) C11orf95-MKL2 75-85
Lipoma t(3;12)(q27;q14) HMGA2-LPP 20–25
t(12;13)(q13;q14) HMGA2-LHFP *
t(3;13)(q27;q14) LPP-LHFP *
t(Y;12)(q12;q14) ?-HMGA2 *
Lipoblastoma t(2;8)(q31;q12) COL3A1-PLAG1 50-75
t(8;8)(q24;q12) HAS2-PLAG1 *
t(7;8)(q21;q12) COL1A2-PLAG1 *
t(8;14)(q12;q24) RAD51B-PLAG1 *
Spindle cell/ pleomorphic lipoma - 13/del(13)(q14) RB1 40–48
del(16)(q13) - 40–50
Hibernoma del(11)(q13-21) MEN1 66–80
Atypical lipomatous tumor/well differentiated
liposarcoma
amp(12)(q14-15) MDM2 80–90
Supernumerary ring - 75–90
Myxoid liposarcoma t(12;16)(q13;p11) FUS-DDIT3 90–95
del(10)(q23) PTEN 7–12
t(12;22)(q13;q12) EWSR1-DDIT3 *
t(12;22;20)(q13;q12;q11) EWSR1-DDIT3 *
Fibroblastic/myofibroblastic Tumor
Nodular fasciitis t(17;22)(p13;q13) MYH9-USP6 90–92
Elastofibroma amp(X)(q12-q22) - 16–30
Fibroma of tendon sheath t(2;11)(q31;q12) - #
t(9;11)(p24;q13) - #
Desmoplastic fibroblastoma t(2;11)(q31;q12) - #
t(11;17)(q12;p11) - #
Cellular angiofibroma del(13)(q14) RB1, FOXO1 54–80
Mammary-type myofibroblastoma del(13)(q14) RB1, FOXO1 70-92
Tenosynovial giant cell tumor t(1;2)(p13;q37) CSF1-COL6A3 50–80
Giant cell fibroblastoma t(17;22)(q22;q13) COL1A1-PDGFB 80–92
Dermatofibrosarcoma protuberans t(17;22)(q22;q13) COL1A1-PDGFB 74–90
Supernumerary ring - 50–65
Inflammatory myofibroblastic tumor t(1;2)(q21;p23) TPM3-ALK 25-30
t(2;19)(p23;p13) TPM4-ALK
t(2;17)(p23;q23) CLTC-ALK
t(2;11) (p23;p15) CARS-ALK
inv(2)(p23q35) ATIC-ALK
t(2;4)(p23;q27) SEC31A-ALK
t(2;12)(p23;p12) PPFIBP1-ALK 10-20
t(2;5)(p23;q35) NPM1-ALK
t(2;2)(p21;p23) EML4-ALK
t(2;1)(p21;q21) TPM3-ALK
t(2;19)(p21;p13) TPM4-ALK
t(2;2)(p23;q13) RANBP2-ALK
t(6;3)(q22;q12) TFG-ROS1 6-10
t(6;17)(q22;p13) YWHAE-ROS1
t(5;12)(q32;q13) NAB2-PDGFRB *
Low grade fibromyxoid sarcoma t(7;16)(q33;p11) FUS-CREB3L2 60-80
t(11;16)(p11;p11) FUS-CREB3L1 3-6
Supernumerary ring - 25-42

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Table 1. Continued
Tumor Type Chromosomal Translocation Genes Involved Freqency (%)
Myoinflammatory fibroblastic sarcoma t(1;10)(p22;q24) TGFBR3-MGEA5 62-80
amp(3)(p12) VGLL3 37-50
Infantile fibrosarcoma t(12 ;15) (p13;q25) ETV6-NTRK3 75-90
Solitary fibrous tumour inv(12)(q13q13) NAB2-STAT6 44-55
Congenital fibrosarcoma t(12;15)(p13;q25) ETV6-NTRK3 90-99
Sclerosing epithelioid fibrosarcoma t(11;22)(p11;q12) EWSR1-CREB3L1 80-90
t(12;16)(q13;p11) DDIT3-FUS 10-20
t(7;16)(q33;p11) FUS-CREB3L2 *
t(11;16)(P13;p11) FUS-CREB3L1 *
So-called Fibrohistiocytic tumor
Tenosynovial giant cell tumour t(1;2)(p11;q35-36) CSF1-COL6A3 50-64
Epithelioid fibrous histiocytoma t(2;10)(q22;p22) VCL-ALK 80-88
t(2;5)(p23;q35) SQSTM1-ALK *
Smooth muscle tumor
Benign metastasizing leiomyoma del(19)(q13.3), del(22)(q12) - #
Uterine leiomyoma t(12;14)(q14;q22) HMGA2-ALDH2 17-20
Pericytic (perivascular) tumor
Myopericytoma t(7;12)(p22;q13) ACTB-GLI1 #
Skeletal muscle tumor
Embryonal rhabdomysarcoma del(11)(p15.5) IGF2, H19, CDKN1C, HOTS 35-45
Alveolar rhabdomyosarcoma t(2;13)(q35;q14) PAX3-FOXO1 60-85
t(1;13)(p36;q14) PAX7-FOXO1 15-20
t(2;2)(q35;p23) PAX3-NCOA1 10-18
t(2;8)(q35;q13) PAX3-NCOA2 *
amp(12)(q13-15) GLI1, CDK4, MDM2 22-56
amp(2)(p24) MYCN 16-50
Vascular tumor
Epithelioid haemangioma t(1;3)(p36;q25) WWTR1-CAMTA1 70-90
t(X;11)(p11;q22) YAP1-TFE3 *
t(19;19)(q13;q13) ZFP36-FOSB *
t(19;1)(q13;q22) FOS-LMNA *
t(19;10)(q13;p13) FOS-VIM *
Pseudomyogenic haemangioendothelioma t(7;19)(q22;q13) SERPINE1-FOSB 20-30
Epithelioid hemangioendothelioma t(11;X)(q22;p11) YAP1-TFE3 80-94
t(1;3)(p36;q23) WWTR1-CAMTA1 77-85
Chondro-osseous tumor
Chondromyxoid fibroma inv(6)(p25q13) - 75-80
del(6)(q24) - 20-40
t(6;17)(q23;p13) BCLAF1-RAP1GAP2 15-20
t(6;9)(q25;q22) COL12A1-? 6-20
Mesenchymal chondrosarcoma del(8)(q13;q21)/t(8;8)(q21;q13) HEY1-NCOA2 70-80
Nerve sheath tumor
Melanotic schwannoma del(2)(p16)/amp(2)(p16) CNC2 70-80
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Table 1. Continued
Tumor Type Chromosomal Translocation Genes Involved Freqency (%)
Perineurioma - 22/del(22)(q12) NF2 75-80
Supernumerary ring -
Schwannoma - 22q NF2, SMARCB1 40
Ewing sarcoma
Ewing sarcoma t(11;22)(q24;q12) EWSR1-FLI1 80-90
t(21;22)(q22;q12) EWSR1-ERG 12-15
t(7;22)(p2;q12) EWSR1-ETV1 5-10
t(17;22)(q21;q12) WESR1-ETV4 *
t(2;22)(q35;q12) EWSR1-FEV *
t(20;22)(q13;q12) EWSR1-NFATC2 *
inv(22)(q12q12) EWSR1-ZFG *
t(4;22)(q31;q12) EWSR1-SMARCA5 *
t(6;22)(p21;q12) EWSR1-POU5F1 *
t(2;22)(q31;q12) EWSR1-SP3 *
t(1;22)(p36;q12) EWSR1-PATZ *
t(16;21)(p11;q22) FUS-ERG *
t(2;16)(q35;p11) FUS-FEV *
del(9)(p21) CDKN2A *
t(4;19)(q35;q13) CIC-DUX4 *
t(X;X)(p11;p11) BCOR-CCNB3 *
Tumors of uncertain differentiation
Angiomatoid fibrous histiocytoma t(2;22)(q33;q12) EWSR1-CREB1 75-85
t(12;22)(q13;q12) EWSR1-ATF1 10-14
t(12;16)(q13;p11) FUS-ATF1 *
Extraskeletal myxoid chondrosarcoma t(9;22)(q22;q12) EWSR1-NR4A3 50-75
t(9;17)q22;q11) TAF2N-NR4A3 15-20
t(9;15)(q22;q21) TFC12-NR4A3 *
t(9;22)(q22;q11) EWSR1-NR4A3 *
t(9;17)(q22;q11) TAF15-NR4A3 *
t(9;15)(q22;q21) TCFI2-NR4A3 *
t(9;22)(q22;q15) TFG-NR4A3 *
t(12;22)(q13;q21) EWSR1-CHOP *
Hemosiderotic fibrolipomatous tumor t(1;10)(p22;q24) TGFBR3-MGEA5 70-85
Extraskeletal myxoid chondrosarcoma t(9;22)(q22;q12) EWSR1-NR4A3 50-75
t(9;17)q22;q11) TAF2N-NR4A3 15-20
t(9;15)(q22;q21) TFC12-NR4A3 *
t(9;17)(q22;q11) TAF15-NR4A3 *
t(9;22)(q22;q15) TFG-NR4A3 *
t(12;22)(q13;q21) EWSR1-CHOP *
Alveolar soft part sarcoma t(X;17)(p11;q25) ASPSCR1-TFE3 80-95
Myoepithelioma/myoepithelial carcinoma/mixed tumor t(6;22)(p21;q12) EWSR1-POU5F1 23
t(1;22)(q23;q12) EWSR1-PBX1 16
t(1;16)(p34;p11) FUS-KLF17 9
t(9;22)(q33;q21) EWSR1-PBX3 8
t(19;22)(q13;q12) EWSR1-ZNF444 *
t(12;22)(q13;q12) EWSR1-ATF1 *
Soft tissue angiofibroma t(5;8)(p15;q13) AHRR-NCOA2 30-50
Ossifying fibromyxoid tumor t(6;12)(p21;q24) EP400-PHF1
t(1;6)(p34;p21) MEAF6-PHF1 50-80
t(6;10)(p21;p11) EPC1-PHF1
t(X;22)(p11;q13) ZC3H7B-BCOR *

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Table 1. Continued
Tumor Type Chromosomal Translocation Genes Involved Freqency (%)
Clear cell sarcoma of soft tissue t(12;22)(q13;q12) EWSR1-ATF1 50-75
t(2;22)(p13;q12) EWSR1-CREB1 6-13
t(12;16)(q13;p11) FUS-ATF1 *
Clear cell sarcoma of the kidney t(10;17)(q22;p13) YWHAE-NUTM2E 13-25
Clear cell sarcoma like tumor of GI tract t(12;22)(q13;q12) EWSR1-ATF1 85-90
t(2:22)(q33:q12) EWSR1-CREB1 6-20
Desmoplastic small round cell tumor t(11;22)(p13;q12) EWSR1-WT1 90-99
t(21;22)(q22;q12) EWSR1-ERG *
Extraskeletal Ewing sarcoma t(11;22)(q24;q12) EWSR1-FLI1 80-90
t(17;22)(q12;q12) EWSR1-EIAF 5-10
t(21;22)(q22;q12) EWSR1-ERG *
t(7;22)(q22;q12) EWSR1-ETV1 *
t(2;22)(q36;q12) EWSR1-FEV *
t(16;21)(p11;q22) FUS-ERG *
t(2;16)(q36;p11) FUS-FEV *
Intimal sarcoma amp(12)(q13-14) CDK4, TSPAN31, MDM2, GLI 75-100
Primary pulmonary myxoid sarcoma t(2;22)(q33;q12) EWSR1-CREB1 70-90
PEComa t(X;17)(p11;p13) DVL2-TFE3
t(X; 1)(p11;p34) SFPQ-TFE3 90-100
inv(X)(p11.2q12) NONO-TFE3
t(5;8)(q32;q24) HTR4-ST3GAL1 *
t(3;3)(p21;p13) RASSF1-PDZRN3 *
t(x;14)(q12;q24.1) RAD51B-RRAGB *
Synovial sarcoma t(X;18)(p11;q11) SYT-SSX1 65-80
t(X;18)(p11;q11) SYT-SSX2 31-35
t(X;18)(p11;q13) SYT-SSX4 *
t(X;20)(p11;q13) SS18L1-SSX1 *
Undifferentiated/unclassified sarcoma
Undifferentiated round and spindle cell sarcomas t(4;19)(q35;q13.1) CIC-DUX4 28-30
inv(X)(p11.2p11.4) BCOR-CCNB3 3-12
Round cell Ewing-like sarcoma t(4;19)(q35;q13) CIC-DUX4 60-75
t(20;22)(q13;q12) EWSR1-NFATc2 *
t(6;22)(p21;q12) EWSR1-POU5F1 *
t(4;22)(q31;q12) EWSR1-SMARCA5 *
inv(22)(q12q12) EWSR1-PATZ1 *
t(4;22)(q31;q12) EWSR1-SMARCA5 *
t(1;22)(p36;q12) EWSR1- ZSG *
t(2;22)(q31;q12) EWSR1-SP3 *
t(10;19)(q26;q13) CIC-DUX10 *
t(X;19)(q13;q13) CIC-FOXO4 *
t(16;21)(p11;q22) FUS-ERG *
t(20;16)(q13;p11) FUS-NCATc2 *
inv(X)(p11.4p11.22) BCOR-CCNB3 *
t(12;15)(p13;q25) ETV6-NTRK3 *
Tumors of undefined neoplastic nature
Aneurysmal bone cyst t(16;17)(q22;p13) CDH11-USP6 66-72
Data Sources: http://cancer.sanger.ac.uk/cosmic; https://www.mycancergenome.org; http://www.genenames.org; http://atlasgeneticsoncology.org; http://cgap.nci.
nih.gov/chromosomes; http://www.genecards.org; www.tumorfusions.org.
*Too infrequent to estimate percentage.
#limited reports.
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is identifiable in more than 95% of cases. Com-
monly used FISH probes are included in the Vysis
DDIT3 dual colour, break-apart rearrangement
probe kit.
Synovial sarcoma
Synovial sarcoma is characterized by t(X;18)(p11;q11)
translocation, which is present in virtually all tumours.
The translocation fuses synovial sarcoma translocation
gene (SS18) on chromosome 18 with either synovial
sarcoma X breakpoint 1 (SSX1) (66%) or SSX2 (33%),
located on chromosome Xp11 [32,33]. The FISH test
is highly specific and sensitive for synovial sarcoma.
A characteristic t(X;18)(p11;q11) translocation or var-
iants were found in 90% of synovial sarcomas. The
t(X;18) translocation has not been found in other
sarcomas.
Solitary fibrous tumour
Solitary fibrous tumour comprises a family of soft
tissue lesions usually affecting adults, occurring at
any site, and presumed to be of fibroblastic differen-
tiation. The tumours were thought to derive from
pericytes, but now there is evidence to support a
fibroblastic or myofibroblastic origin. Recurrent
fusions of the two genes, NGFI-A–binding protein 2
(NAB2) and signal transducer and activator of tran-
scription 6 (STAT6), both located near chromosomal
region 12q13, have been identified in solitary fibrous
tumours. The NAB2-STAT6 fusion gene is derived
from an inverted intra-chromosomal fusion of the
NAB2 and STAT6 genes on 12q13 [34,35]. The fusion
product contains the activation domain of STAT6
fused to the early growth response (EGR)-binding
domain of NAB2 [36]. Overexpression of the NAB2-
STAT6 fusion gene induces cell proliferation and acti-
vates expression of EGFR-responsive genes. Chmie-
lecki et al identified the NAB2-STAT6 translocation
by whole exome sequencing from 17 solitary fibrous
tumours and matched blood [34]. This fusion gene
was confirmed in 29 of 55 (55%) solitary fibrous
tumours by exome sequencing. Since the NAB2 and
STAT6 genes are both located near 12q13, the break
apart designed probe may detect some but not all of
the NAB2-STAT6 translocations. Mohajeri et al used
six independent molecular genetic techniques directed
at NAB2 or STAT6 rearrangement to identify NAB2–
STAT6 fusion in 37 of 41 (90%) of the solitary
fibrous tumours evaluated [37].
It should be noted that the NAB2-STAT6 fusion is
not consistently detected by FISH due to the very
close proximity of the two genes [36] and, in this
setting, reverse transcription polymerase chain reaction
or RNA-Seq, is the preferred method of detection.
STAT6 immunostaining is highly sensitive and spe-
cific for detecting NAB2-STAT6 fusion product and is
now becoming standard practice.
Round cell Ewing-like sarcoma
There is a small subset of sarcomas that clinically
and histologically mimic Ewing sarcoma but fail to
exhibit any of the cytogenetic abnormalities reported
for these tumours. Recently cases of ‘Ewing-like sar-
coma’ have been found to have a recurrent chromo-
somal translocation, t(4;19)(q35;q13), resulting in
fusion of capicua homologue (CIC) and double
homeobox 4 (DUX4) [38]. Fusion of the C-terminal
fragment of DUX4 with CIC enhances the transcrip-
tional activity of CIC and deregulates expression of
its downstream targets. CIC-DUX4 fusion protein
directly binds the ETS variant 5 (ETV5) promoter at
a previously unrecognized site and upregulates
expression of this oncogene. Four cases of CIC-
DUX4 sarcoma were identified using a combination
of conventional cytogenetic, RT-PCR, and FISH
methods [39]. FISH was positive for CIC-DUX4
fusion in all four tumours. The distinctive histopatho-
logical features and rapid disease progression may
warrant classification of CIC-DUX4 sarcoma as a
new translocation-associated sarcoma.
Inflammatory myofibroblastic tumour
Inflammatory myofibroblastic tumour is a spindle
cell neoplasm most frequently found in the urinary
bladder but occasionally diagnosed at various body
sites. Although these tumours usually behave in a
benign fashion, they may be difficult to differentiate
from sarcoma or sarcomatoid carcinoma. Roughly
half of inflammatory myofibroblastic tumours have
ALK rearrangements leading to elevated expression
of ALK chimeric protein [40]. The ALK transloca-
tions involve 2p23 with multiple fusion partners,
including TPM3-ALK, RANBP2-ALK, TPM4-ALK,
EML4-ALK, CLTC-ALK, CARS-ALK, ATIC-ALK,
SEC31A-ALK and PPFIBP1-ALK [41,42]. In each
instance, the fusion gene overexpresses ALK due to
promoter swapping. ALK rearrangements may prove
useful for distinguishing inflammatory myofibroblas-
tic tumour from morphologically similar neoplasms.
Therapy targeting tumour cells with ALK gene
rearrangement induces partial tumour remission
[43,44], but, little is known about the pathogenesis of
the 50% of inflammatory myofibroblastic tumours
that lack ALK translocation.
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Besides ALK, C-ROS oncogene 1 (ROS1) and
NTRK3 gene rearrangements, YWHAE–ROS1 and
ETV6–NTRK3 are also found in ALK fusion negative
inflammatory myofibroblastic tumours [45]. Anto-
nescu et al reported six (10%) ROS1 related translo-
cations in a group of 62 cases. Most of the patients
were children, and the tumours were located in the
lung or abdomen [46]. Two (3.2%) inflammatory
myofibroblastic tumour cases showed TFG-ROS1
fusions, t(3;6)(q12;q22).
Alveolar soft part sarcoma
Alveolar soft part sarcoma has a characteristic histo-
pathology but a controversial histogenesis. Alveolar
soft part sarcomas arising in many body sites have a
diagnostic translocation. The rearrangement involves
the alveolar soft part sarcoma locus (ASPSCR1)
located on chromosome 17q25 and the transcription
factor for the immunoglobulin heavy chain enhancer
3 (TFE3) gene, located on chromosome Xp11 [47].
The fusion protein is capable of inducing aberrant
transcription of TFE3-regulated genes and may con-
fer resistance to cell-cycle arrest signals and override
apoptosis. Selvarajah et al investigated 17 alveolar
soft part sarcomas from 11 patients by array compar-
ative genomic hybridization and FISH. FISH identi-
fied the ASPSCR1-TFE3 fusion in all cases [12].
The ASPSCRI-TFE3 [der(17)t(X;17)(p11;q25)]
translocation is found in 80% of alveolar soft part
sarcomas. This translocation is also found in a dis-
tinctive subset of renal cell carcinoma (translocation
renal cell carcinoma) which frequently has a papil-
lary architecture.
Alveolar rhabdomyosarcoma
Alveolar rhabdomyosarcoma (ARMS) is a highly
aggressive soft tissue sarcoma associated with trans-
locations involving PAX3-FOXO1 [t(2;13)(q35;q14)]
or PAX7-FOXO1 [t(1;13)(p36;q14)] reportedly
accounting for 55–80% and 15–22% of ARMS,
respectively [48]. These translocations generate
fusion proteins that function as transcriptional activa-
tors with oncogenic effects. FISH testing has higher
sensitivity and specificity than RT-PCR assay for
these fusion transcripts [49]. FISH analysis using the
FOXO1split-apart probe adds the ability to detect
variant FOXO1 rearrangements not detectable by
PCR.
Clear cell sarcoma of soft tissue
Clear cell sarcoma of soft tissue is a rare mesenchy-
mal malignancy mainly occurring in young to
middle-aged adults of either sex, typically in the soft
tissue of the lower extremities. The tumour is aggres-
sive with a high frequency of local recurrence and
distant metastasis. Almost all (90%) clear cell sarco-
mas are associated with EWSR1-ATF1 translocation,
t(12;22)(q13;q12), while a smaller subset of tumours
(6%) bear an EWSR1-CREB1 translocation [50]. The
specific translocation is unrelated to tumour progno-
sis. In a group of 33 clear cell sarcomas, RT-PCR
using RNA extracted from formalin-fixed, paraffin-
embedded tissues demonstrated transcripts of the
EWSR1-ATF1 (31/33) or EWSR1-CREB1 fusion gene
(2/33) [51].
Chromosomal translocations in other solid
tumours
A growing number of fusion oncogenes have been
also associated with some common adult epithelial
tumors, such as adenocarcinomas of the lung, pros-
tate, colon, kidney, breast and other epithelial solid
tumours (Table 2).
Chromosomal translocations mainly associated
with lung cancer
EML4-ALK translocation. ALK is a tyrosine kinase
member of the insulin receptor superfamily normally
expressed only in certain neurons of the developing
central nervous system. Fusions of ALK with echino-
derm microtubule-associated protein-like 4 (EML4), a
protein involved in microtubule assembly, results in
constitutive activation of the ALK kinase [52,53].
The ALK fusion oncogene was first identified in ana-
plastic large-cell lymphoma, in which a t(2;5) chro-
mosome rearrangement activates the ALK kinase by
fusion with the nucleophosmin gene (NPM1) on
chromosome 5. ALK fusions have been reported in
non-small cell lung carcinoma, breast cancer, colo-
rectal cancer, renal cancer and other tumour types
[41,42,54,55]. The common FISH test for ALK rear-
rangement uses dual colour labelled probes covering
the ALK gene and 30 flanking region of ALK (Figure
3). The year 2013 was the first time that the FDA
simultaneously approved a novel anticancer drug (cri-
zotinib, Pfizer) and its companion FISH detection kit
(ALK FISH probe kit, Abbott Molecular), highlight-
ing the critical role of FISH triage for guiding ALK-
targeted therapy [56,57]. A FDA approved Vysis
ALK break apart FISH probe kit is recommended by
the College of American Pathologists (CAP). In gen-
eral, a sample is considered positive if >15% of cells
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Table 2. Chromosome alterations in solid tumors of epithelial origin.
Tumor Type Chromosome alteration Gene Involved Frequency (%)
Head and Neck/Salivary gland
Pleomorphic adenoma t(3;8)(p21;q12) CTNNB1-PLAG1
t(5:8)(p13;q12) LFIR-PLAG1
r(8)(p12q12) FGFR1-PLAG1
t(8;8)(q12;q12) CHCHD7-PLAG1 30–40
t(8;8)(q11;q12) TCEA1-PLAG1
t(7;8)(q21;q12) COL1A2-PLAG1
t(8;8)(q24;q12) HAS2-PLAG1
t(9;12)(p22;q14) HMGA2-NFIB 5-8
t(3;12)(p14;q14) HMGA2-FHIT
Adenoid cystic carcinoma t(6;9)(q22;p23) MYB-NFIB 30–50
Clear cell odontogenic carcinomas t(22;12)(q12;q13) EWSR1-ATF1 63–82
Hyalinizing clear cell carcinoma t(22;12)(q12;q13) EWSR1-ATF1 60–85
Mucoepidermoid carcinoma t(11;19)(q21;p13) CRTC1-MAML2 50–70
t(15;11)(q26;q21) CRTC3-MAML2 2–6
t(1;11)(q21;q21) CRTC2-MAML2 *
t(6;22)(p21;q12) EWSR1-POU5F1 *
Mammary analogue secretory carcinoma t(12;15)(p13;q25) ETV6-NTRK3 85–94
NUT midline carcinoma t(15;19)(q13;p13) BRD4–NUTM1 70–80
t(15;9)(q13;q34) BRD3-NUTM1 10–15
Salivary duct carcinoma del(10)(q23) PTEN 40–50
t(12;8)(q14;q12) HMGA2-PLAG1 22-50
Solitary dermal cylindroma t(6;12)(q23;q23) MYB–NFIB 60–80
Squamous cell carcinoma of the head and neck Amp(8)(p11) FGFR1 9–15
Thyroid gland
Papillary thyroid carcinoma inv(10)(q11q21) RET-CCDC6(PTC1) 60-70
inv(10)(q11q10) RET-NCOA4(PTC3) 22-30a
t(1;15)(q21;q25) NTRK1-TPM3 12
t(10;17)(q11;q23) RET- 5-11a
PRKAR1A(PTC2)
t(12;15)(p13;q25) ETV6-NTRK3a 2-14a
t(10;14)(q11;q32) RET- GOLGA5 *
t(7;10)(q32;q11) RET-TRIM24 *
t(10;14)(q11;q32) RET-TRIM27 *
t(1;10)(p13;q11) RET-TRIM33 *
t(10;14)(q11;q22) RET-KTN1 *
t(8;10)(p21;q11) RET-PCM1 *
t(6;10)(p21;q11) RET-TRIM27 *
t(8;10)(p11;q11) RET-HOOK3 *
t(10;12)(q11;p13) RET-ERC1 *
t(10;18)(q11;q21) RET-MBD1 *
t(2;2)(p22;p23) STRN-ALK *
t(7;7)(q21;q34) AKAP9-BRAF *
Follicular thyroid carcinoma t(2;3)(q13;p25) PAX8-PPARc 30-35
Medullary thyroid carcinoma t(10;17)(q11;p13) RET-MYH13 #

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Table 2. Continued
Tumor Type Chromosome alteration Gene Involved Frequency (%)
Lung
Lung adenocarcinoma inv(2)(p21p23) EML4-ALK 3-7
t(2;3)(p23;q12) TFG-ALK
t(2;10)(p23;p11) KIF5B-ALK
t(2;14)(p23;q32) KLC1-ALK
t(2;9)(p23;q31) PTPN3-ALK 1-2
t(2;2)(p23;p22) STRN-ALK
t(2;4)(p23;q21) SEC31A-ALK
t(2;7)(p23;q11) HIP1-ALK
t(6;10)(q22;q21) CCDC6-ROS1
t(6;7)(q22;p22) KDELR2-ROS1
t(6;12)(q22;q14) LRIG3-ROS1
t(6;20)(q22;q13) SDC5-ROS1
t(6;5)(q22;q32) CD74-ROS1 2-3
t(6;19)(q22;q13) FIG-ROS1
t(6;6)(q22;q25) EZR-ROS1
t(6;1)(q22;q21) TPM3-ROS1
t(4;6)(p15;q22) SLC34A2-ROS1
t(1;17)(q23;p11) MPRIP-NTRK1
t(1;5)(q23;q33) CD74-NTRK1 1-3
inv(1)(q23q21) TPM3-NTRK1
t(10;10)(q11;p11) KIF5B-RET
t(10;10)(q11;q21) CCDC6-RET 1
t(10;10)(q11;q11) NCOA4-RET
t(1;10)(p13;q11) TRIM33-RET
t(9;7)(q21;q33) TRIM24-NTRK2 #
Primary pulmonary myxoid sarcoma t(2;22)(q33;q12) EWSR1-CREB1 70-90
Pleura and peritoneum
Mesothelioma t(14;22)(q23;q12) EWSR1-YY1 *
Gastrointestinal tract
Colorectal carcinoma t(6;6)(q22;q22) PTPRK-RSPO3 5-8
t(11;2)(p15;p11) EIF3E-RSPO2 3-4
t(2;2)(p23;p23) WDCP-ALK
inv(2)(p21p23) EML4-ALK
2-5
t(4;6)(p15;q22) SLC34A2-ROS1 0.4-0.8
t(10;10)(q25;q25) NAV2-TCF7L1 *
t(8;8)(q23;q23) VTI1A-TCF7L2 *
t(1;1)(q21;q23) NTRK1-TPM3 *
Esophageal adenocarcinoma t(3;8)(p14.2;q24) FHIT-RNF139 #
Fibrolamellar hepatocellular carcinoma t(19;19)(p13.1;p13.2) DNAJB1-PRKACA 92–100
Intrahepatic cholangiocarcinoma t(1;1)(q23;q25) RABGAP1L-NTRK1 *
Gynecological tract
Endometrial stromal sarcoma t(7;17)(p15;q11) JAZF1-SUZ12 40-50
t(7;10)(p13;q23) YWHAE-NUTM2A 20-30
t(7;10)(p13;q23) YWHAE -NUTM2B
t(1;6)(p34;p21) MEAF6-PHF1
t(6;7)(p21;p15) JAZF1-PHF1 6–10
t(6;10)(p21;p11) EPC1-PHF1
Ovarian papillary cystadenocarcinoma t(6;14)(q21;q24) - 32-40







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Table 2. Continued
Tumor Type Chromosome alteration Gene Involved Frequency (%)
Breast
Secretory breast carcinoma t(12;15)(p13;q25) ETV6-NTRK3 56–100
t(8;11)(p12;q14) TENM4-NRG1 *
t(3;6)(q26;q25) TBL1XR1-RGS17 *
dic(8;11)(p12;q14) TENM4-NRG1 *
Triple-negative breast carcinoma t(1;1)(p13;q44) MAGI3–AKT3 1
The urinary system and male genital organs
Oncocytoma t(5;11)(q35;q13) - #
t(6;9)(p12;p24) - #
Metanephric adenoma t(1;22)(q22;q13) EWSR1-PBX1 *
t(15;16)(q21;p13) - *
t(9;15)(p24;q24) - #
inv(12)(q13q15) - #
t(1;22)(q22;q13) - #
t(15;16)(q21;p13) - #
Clear cell renal cell carcinoma del(3)(p11-pter) VHL, PBRM1, BAP1, 70–90
SETD2
del(14)(q23) HIF1A 35–40
Papillary renal cell carcinoma 1 7 MET 80
1 17 - 85
-Y - 70
Renal carcinomas associated with Xp11.2
translocations
t(X;1)(p11.2;q21) PRCC–TFE3 60-70
t(X;1)(p11.2;p34) SFPQ–TFE3 10-20
t(X;17)(p11.2;q25) ASPSCR1–TFE3 5-7
inv(X)(p11.2q12) NONO–TFE3 *
t(X;17)(p11.2;q23) CLTC–TFE3 *
t(X;17)(p11.2;q21.3) LUC7L3-TFE3 *
t(X;19)(p11.2;p13.3) KHSRP-TFE3 *
Renal cell carcinoma associated with t(6;11)
translocations
t(6;11)(p21;q12) MALAT1-TFEB 90–100
t(6;6)(p21;q11) KHDRBS2-TFEB #
Chromophobe renal cell carcinoma - 1 -
- 2 -
- 6 -
210 - 70–90
- 13 -
- 17 -
- 21 -
Renal medullary carcinoma t(1;22)(q41;q11) SMARCB1-CAPN2 #
t(15;22)(q22;q11) SMARCB1-RORA #
t(11;22)(q21;q11) SMARCB1-MAML2 #
t(11;22)(q13;q11) SMARCB1-MALAT1 #
ALK translocation associate renal cell carcinoma b t(2;1)(p23;q21) TPM3-ALK 100
t(2;10)(p23;q22) VCL-ALK #
Wilms tumor i(17)(q10) - *
i(7)(q10) - #
Clear cell sarcoma of the kidney t(10;17)(q22;p13) YWHAE-NUTM2E 13-25
Urothelial carcinoma Polysomy 3 -
Polysomy 7 -
80–94cPolysomy 17 -
del(9)(p21) CDKN2A


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Table 2. Continued
Tumor Type Chromosome alteration Gene Involved Frequency (%)
t(4;7)(p16;q22) FGFR3-BAIAP2L1 5-9
t(4;4)(p16;p16) FGFR3-TACC3 3-6
t(12;16)(q13;p13) SCN8A-GRIN2A #
Prostatic adenocarcinoma t(21;21)(q22;q22) TMPRSS2-ERG
t(21;16)(q22;q13) HERPUD1-ERG
47–79
t(21;1)(q22;q32) SLC45A3-ERG
t(21;8)(q22;q24) NDRG1-ERG
t(7;22)(p21;q22) ETV1-ERG *
t(17;22)(q21;q22) ETV4-ERG *
t(7;21)(p21;q22) TMPRSS2-ETV1
t(7;1)(p21;q32) SLC45A3-ETV1
t(7;15)(p21;q21) C15orf21-ETV1
t(7;7)(p21;q15) HNRPA2B1-ETV1 7–10
t(7;11)(p21;p15) ASCL3-ETV1
t(7;14)(p21;q13) EST14-ETV1
t(7;17)(p21;p13) HERVK17-ETV1
t(1;1)(q32;q32) TMPRSS2-ETV4 *
t(17;21)(q21;q22) CANT1-ETV4 *
t(17;17)(q21;q25) KLK2-ETV4 *
t(3;21)(q27;q22) TMPRSS2-ETV5 *
t(3;1)(q27;q32) SLC45A3-ETV5 *
t(17;19)(q21;q13) SLC45A3-ELK4 *
t(3;8)(p25;q22) ESRP1-RAF1 *
t(7;1)(q34;q32) SLC45A3-BRAF *
del(10)(q23) PTEN 40-70
Testicular germ cell tumor i(12p) - 67–83
Skin
Spitz nevi t(5;6)(q33;q22) PWWP2A-ROS1
t(6;6)(p22;q22) HLA-A-ROS1
t(6;12)(q22;p11) PPFIBP1-ROS1
t(6;15)(q22;q21) MYO5A-ROS1
t(6;12)(q22;p13) ERC1-ROS1 15–20
t(6;12)(q22;q24) CLIP1-ROS1
t(6;12)(q22;q24) ZCCHC8-ROS1
t(6;10)(q22;q25) SHTN1-ROS1
t(3;6)(q12;q22) TFG-ROS1
t(2;2)(p23;p23) DCTN1-ALK 11–15
t(1;2)(q23;p23) TPM3-ALK
t(1;17)(q23;p13) TP53-NTRK1 7–16
t(1;1)(q23;q22) LMNA-NTRK1
t(10;14)(q11;q32) GOLGA5-RET
3
t(10;10)(q11;p11) KIF5B-RET
t(7;19)(q34;q13) CEP89-BRAF *
t(7;19)(q34;q13) LSM14A-BRAF *
t(2;7)(q37;q31) LRRFIP1-MET *





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Table 2. Continued
Tumor Type Chromosome alteration Gene Involved Frequency (%)
Melanoma amp(11)(q13) CCND1
amp(6)(p25) RREB1 54–82d
amp(6)(q23) MYB
t(1;7)(q32;q34) SLC45A3-BRAF *
t(4;7)(q25;q34) PAPSS1-BRAF *
t(7;7)(q33;q34) TRIM24-BRAF *
t(7;7)(q34;q34) AGK-BRAF *
t(7;7)(p22;q34) MAD1L1-BRAF *
t(7;7)(q11;q34) KCTD7-BRAF *
t(7;7)(p13;q34) NUDCD3-BRAF *
t(7;11)(q34;p15) SOX6-BRAF *
t(7;7)(q22;q34) ZKSCAN5-BRAF *
t(7;19)(q34;p13) PLIN3-BRAF *
t(7;7)(q22;q31) ZKSCAN1-MET *
t(7;7)(q22;q31) TRIM4-MET *
t(3;8)(p25;q22) ESRP1-RAF1 *
Nervous system
Oligodendrogliomas del(1)(p36), del(19)(q13) - 77-92
t(1;19)(q10;p10) - #
Glioblastomas del(10)(q23) PTEN 43
t(7;7)(q31;q31) PTPRZ1-MET 15-35
t(4;4)(p16;p16) FGFR3-TACC3
5-8
t(4;8)(p16;p11) FGFR1-TACC3
t(3;?)(p27;?) ?-BCL6 5
t(7;7)(p11;p12) LANCL2- SEPT14 *
Angiocentric glioma t(6;6)(q23;q26) MYB-QKI 80
Pilocytic astrocytoma t(7;7)(q34;q34) KIAA1549-BRAF 64–73
t(7;5)(q34;q35) RNF130-BRAF *
t(9;6)(q21;q26) QKI-NTRK2 *
Medulloblastoma i(17q) - 30–50
t(1;19)(q23;p13) E2A-PBX1 #
Meningioma del(22)(q12) NF2 50-60
t(12;22)(p13;q12) MN1-ETV6 #
t(1;19)(q21;q13.3) - #
Ependymoma -del(22)(q11) - 20–30
t(11;11)(q13;q13) C11orf95-RELA 71–80
t(2;14)(p23;q22) KTN1-ALK #
del(2)(p16p23) CCDC88A-ALK #
Extraventricular neurocytoma t(1;19)(q10;p10) - 17-20
Papillary glioneuronal tumor t(9;17)(q31;q24) SLC44A1-PRKCA #
Data Sources: http://cancer.sanger.ac.uk/cosmic; https://www.mycancergenome.org; http://www.genenames.org; http://atlasgeneticsoncology.org; http://cgap.nci.
nih.gov/chromosomes; http://www.genecards.org; www.tumorfusions.org.
*Too infrequent to estimate percentage
#limited report
aHigher incidence in radiation induced thyroid cancers
b50% with sickle-cell trait
cThe UroVysion Bladder Cancer Kit (UroVysion Kit) is FDA approved and designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus in
urothelial tumors.
dThe Vysis Melanoma FISH Probe Kit is designed to detect copy number of the RREB1 (6p25), MYB (6q23), CCND1 (11q13) genes and of centromere 6 in mela-
nocytic lesions.

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are positive for ALK separation of the green and
orange signals.
ROS1 translocation. ROS1 is a receptor tyrosine
kinase of the insulin receptor family. The ROS1 rear-
rangements lead to a constitutively activated fusion
kinase, and are detected in 1.2–1.7% of lung adeno-
carcinoma cases [58–60]. ROS1 activation stimulates
other downstream signalling proteins including
AKT1, MAPK1, MAPK3, IRS1 and PLCG2 [59].
Patients with ROS1 translocation are significantly
younger than most patients with lung cancer and are
more likely to be never-smokers. Their cancers tend
to be adenocarcinoma, and their tumours have a tend-
ency towards higher grade. Several genes may serve
as fusion partners for ROS1 including SDC4,
SLC34A2, CD74, GOPC, and EZR, yet each of the
ROS1 fusion products leads to constitutive ROS
kinase activation [61]. A dual probe break-apart
method is used to detect ROS1 rearrangement as with
ALK rearrangement. Criteria similar to those used for
ALK rearrangement screening are used to evaluate
the ROS1 FISH test.
ROS1 fusions are also found in meningioma, chol-
angiocarcinoma and glioblastoma, but no systematic
investigation of tyrosine kinase inhibitors has been
published for ROS1-fusion positive tumours of these
primary sites [62,63]. The reported incidence of
ROS1 translocation is also low in other tumour types:
8.7% (2/23) of cholangiocarcinomas, 0.5% (1/200) of
ovarian carcinomas, 0.6% (3/495) of gastric adeno-
carcinomas, 0.8% (2/236) of colorectal carcinomas,
7.7% (2/26) of inflammatory myofibroblastic
tumours, 2.9% (1/34) of angiosarcomas and 5% (1/
20) of epithelioid haemangioendotheliomas [63–66].
Rearranged during transfection translocation. Novel
chromosomal translocations involving the rearranged
during transfection (RET) tyrosine kinase gene were
reported recently [61,67]. The RET gene belongs to
the cadherin superfamily, and encodes a cell surface
receptor tyrosine kinase that transduces signals for
cell growth and differentiation [67,68]. Several RET
rearrangements have been identified in non-small cell
lung carcinomas, including KIF5B-RET, CCDC6-
RET, NCOA4-RET, and TRIM33-RET.
Figure 3. Signal patterns of ALK split-apart probes. The commonly used ALK split-apart FISH test uses dual colour labelled probes
covering the ALK gene (yellow) and 30 flanking region of ALK (red). When translocation occurs, the normal closely approximated sig-
nal pattern separates into distinct yellow and red signals (in commercial FISH ALK translocation kits Green and Red signals may be
used). Since ALK translocations involve multiple fusion partners, a split-apart design ensures that the probe set will uncover ALK
translocations with most of the possible fusion partners.
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RET gene translocation occurs in approximately 1–
2% of non-small cell lung carcinomas and defines a
clinically distinct subset of non-small cell lung carci-
nomas. Patients with adenocarcinomas with RET
fusion tend to be younger than most patients with lung
cancer and they are more likely to be never-smokers
[69]. In a study of 936 patients with non-small cell
lung carcinoma, the RET fusion gene was exclusively
detected in 13 patients (11/633, 1.7% in adenocarci-
noma; 2/24, 8.3% in adenosquamous cell carcinoma)
[70]. Of the 13 RET fusion-positive patients, 9 (69%)
had KIF5B-RET, 3 (23%) had CCDC6-RET, and 1
(7.6%) had NCOA4-RET fusion. Their tumours tended
to be poorly differentiated carcinomas that exhibited
early lymph node metastasis. Drilon et al found RET
fusions in 5 of 31 patients and showed that the RET
kinase can be effectively inhibited by several small
molecule inhibitors [71]. Followup imaging conducted
after 4 and 12 weeks of therapy confirmed a partial
response with a 66% decrease in measurable disease
in the lungs and pleura.
EWSR1-CREB1 translocation in primary pulmonary
myxoid sarcomas. In the 2015 World Health Organiza-
tion (WHO) Classification of Tumours of the Lung,
Pleura, Thymus and Heart, pulmonary myxoid sarcoma
with EWSR1-CREB1 translocation was introduced as a
new entity [72]. Primary pulmonary myxoid sarcoma
is rare, and arises most frequently in young females.
The tumour consists of lobules with delicate, lacelike
strands and cords of mildly atypical round or spindle
cells in a prominent myxoid stroma. In addition to dis-
playing a distinct morphology, it bears a EWSR1-
CREB1 translocation in 70% of cases [73]. It should
be noted that EWSR1-CREB1 translocation is not
unique for this entity; it can also be observed in clear
cell sarcoma-like tumour of the gastrointestinal tract
and angiomatoid fibrous histiocytoma (Table 1)
Chromosomal translocations mainly associated
with kidney cancer
TFE3 translocation
Renal cell carcinomas associated with Xp11.2 trans-
location are uncommon renal tumours that were rec-
ognized as a distinct entity in the 2016 World Health
Organization classification of Tumours of the Urinary
System and Male Genital Organs [74]. These neo-
plasms comprise the majority of paediatric renal cell
carcinomas and a smaller percentage of adult renal
cell carcinomas. There are several different transloca-
tions involving chromosome Xp11.2, resulting in
Figure 4. Genomic translocation relationships presented by Circos
plot. Circos applies a circular ideogram displaying relationships
between genomic intervals. The Circos plot is a ring composed of
all chromosomes in proportionate size clockwise from 1 to Y. This
graphic representation is used to visualize chromosomal transloca-
tions associated with a clinical entity. A specific translocation is
shown with a line connecting the two chromosome partner loci
involved in each translocation. The chromosomal translocations that
may be involved in Xp11 translocation renal cell carcinomas are
shown in A, including inv(X)(p11.2;q12) [NonO-TFE3] (Red),
t(X;1)(p11.2;p34) [PSF-TEF3] (Gray), t(X;1)(p11.2;q21) [PRCC-TFE3]
(Blue), t(X;3)(p11.2;q23) [unknown-TFE3] (Black), t(X;10)(p11.2;q23)
[unknown-TFE3] (Yellow), t(X;17)(p11.2;q23) [CLTC-TFE3] (Magenta),
t(X;17)(p11.2;q25) [ASPL-TFE3] (Green), t(X;19)(p11.2;q13.1)
[unknown-TFE3] (Purple). Translocations involved in TFEB transloca-
tion renal cell carcinoma are shown in B, t(6;11)(p21;q13)
[MALAT1-TFEB] (Blue), t(6;17)(p21;q25) [ASPSCR1-TFEB] (Red).
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gene fusions of the TFE3 gene with various activat-
ing partners. At least five different fusion partners
for TFE3 have been characterized, including
ASPSCR1, PRCC, SFPQ, CLTC and NONO (Figure
4) [75,76]. Variant translocations with unknown
fusion partners include t(X;3)(p11.2;q23) and
t(X;10)(11.2;q23). Different gene fusions in Xp11.2
translocation renal cell carcinoma may be associated
with different morphological features [77,78].
The TFE3 break-apart FISH assay has proven use-
ful for detecting TFE3 gene fusions in Xp11.2 trans-
location renal cell carcinoma, and the FISH assay, in
comparison with immunohistochemical evaluation, is
less often adversely affected by technical and fixation
issues. Rao et al analysed 24 poorly differentiated
renal cancers with break-apart TFE3 FISH [79].
Seventeen cases showed TFE3 rearrangement associ-
ated with Xp11.2 translocation by FISH, including
seven previously unclassified renal cell tumours, sup-
porting the diagnostic value and clinical application
of FISH for enigmatic renal tumours. On the basis of
commercially available and widely tested break-apart
FISH assays, the TFE3 split-signal pattern was con-
sidered positive when 10% of the tumour nuclei
showed separation of the two coloured signals by
more than one signal diameter (Figure 5).
Transcription factor EB translocation
The t(6;11) translocation renal cell carcinoma is rare
and usually bears a translocation between transcrip-
tion factor EB (TFEB) and MALAT1 on chromosome
Figure 5. Signal patterns of TFE3 split-apart probes. Renal cell carcinomas associated with Xp11.2 translocation involve several differ-
ent translocations resulting in gene fusions of the TFE3 gene with various fusion partners. The break-apart FISH assay uses probes
both upstream (yellow) and downstream (red) to TFE3 showing different signal patterns in female (A) and male (B) patients. A posi-
tive result in a female patient shows a fused or closely approximated normal yellow-red signal pair (uninvolved X chromosome) and
either a pair of split-apart signals or a single yellow or red signal due to section truncation artifact. Because males have only one X-
chromosome, a positive result in a male patient consists either of a pair of split-apart yellow and red signals, or of a single yellow or
red signal due to section truncation.
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11q12, but rarely TFEB may partner with KHDRBS2
on chromosome 6q11 (Figure 4B) [80]. Renal cell
carcinomas with t(6;11)(p21;q12) are characterized by
translocation involving TFEB. Identification of either
TFEB protein overexpression or t(6;11) translocation
is useful for the diagnosis of TFEB renal cell carci-
noma. Cytogenetic karyotypic analysis and RT-PCR
are also common methodologies for identifying this
translocation. Unfortunately, these methods are lim-
ited by the need for fresh viable tumour cells for cul-
ture or flash frozen tissue to quantitatively assay
TFEB mRNA. More recently, a break-apart FISH
assay to detect TFEB gene translocation has been
validated on formalin-fixed paraffin-embedded tissues,
and appears to be superior to the TFEB IHC assay.
Rao et al reported seven patients with TFEB renal
cell carcinoma confirmed diagnostically by using
FISH technology. All seven cases were TFEB positive
by both fusion and split-apart probe designs [81].
SMARCB1/SMARCB1 genetic alterations and ALK
translocation
Renal medullary carcinoma is a rare, aggressive
tumour with a poor clinical outcome. It belongs to a
SMARCB1-deficient tumour family [82]. Inactivation
of tumour suppressor gene SMARCB1 is the hallmark
of this tumour. Cheng et al studied a total of 19 renal
cancers that included 5 renal medullary carcinomas,
2 paediatric rhabdoid tumours of kidney, 10 high
grade renal cell carcinomas and 2 urothelial carcino-
mas [83]. All renal medullary carcinomas were from
African American patients with sickle-cell trait who
presented with extensive extrarenal metastases at the
time of diagnosis. All five renal medullary carcino-
mas and two renal rhabdoid tumours showed com-
plete loss of SMARCB1 expression. Another study
by Calderaro et al found recurrent alterations involv-
ing chromosome 22q11 in each of four renal medul-
lary carcinomas associated with sickle-cell trait.
Figure 6. Signal patterns of TMPRSS2-ERG translocation by tri-colour split-apart probes. The TMPRSS2-ERG tri-colour fused probe
uses three different colour probes recognizing the up-stream end of TMPRSS2 (orange), and both up- and down- stream ends of ERG
(yellow, red), respectively. The probes hybridizing to the wild type TMPRSS2/ERG loci show the normal co-localized red-yellow-orange
pattern (A). TMPRSS2/ERG loci rearrangement via breaks in both ERG and TMPRSS2 genes leads to a red-orange fusion of ERG down-
stream signal to the TMPRSS2 signal. The ERG up-stream signal may either split from the down-stream sequence as in (B), or be
deleted entirely as shown with the signal pattern shown in (C).
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Each of these showed hemizygous SMARCB1 dele-
tion [84]. RNA sequencing further identified fusion
transcripts involving SMARCB1 in these tumours.
The transcripts resulted from balanced translocations
disrupting SMARCB1 and fusing it to various partners
including CAPN2, RORA, MAML2 and MALAT1.
ALK translocation was also reported in renal
medullary carcinomas from young patients with
sickle-cell trait to be associated with VCL-ALK trans-
location [85]. The incidence of ALK rearrangement
associated with all renal cell carcinomas is low, with
an overall frequency of <1%. In a study including
534 adult renal cell carcinoma patients, ALK rear-
rangements occurred in two papillary renal cell carci-
nomas [86]. More recently, Kusano et al reported
two cases of RCC harbouring a novel STRN-ALK
fusion [87]. In both cases, the patients were in their
30s at the time of nephrectomy.
Chromosomal translocations mainly associated
with prostate cancer
A significant event in prostate carcinogenesis
involves gene fusion between members of the E-
twenty-six transforming factor (ETS) family of genes,
including ERG, and the transmembrane protease, ser-
ine 2 (TMPRSS2, 21q22.3) gene [88–91]. The genes
involved are the androgen-regulated gene TMPRSS2
and ETS transcription factor family members, includ-
ing ERG (21q22.2), ETV1 (7p21.2), or ETV4
(17q21). TMPRSS2-ERG gene fusion has been identi-
fied in about 50% of prostate tumours (ranging from
27% to 79%). These fusions appear to represent a
specific early event in prostatic carcinogenesis that
can be observed in high grade prostatic intra-
epithelial neoplasia [90]. The TMPRSS2-ERG rear-
rangement can be identified by both dual colour split
apart probe or by tricolour probes (Figure 6) [92–94].
Chromosomal translocations mainly associated
with breast cancer
A rare variant of breast cancer, secretory breast can-
cer, has a characteristic recurrent translocation
between ETS variant 6 (ETV6) and neurotrophic tyro-
sine kinase type 3 (NTRK3), t(12;15)(p13;q25)
[95,96]. This translocation appears to be the initial
hit required for formation of secretory breast cancer.
Retroviral transfer of ETV6-NTRK3 into murine
mammary epithelial cells resulted in transformed
cells that readily formed tumours in nude mice.
The biological consequence of this translocation is
expression of a chimeric tyrosine kinase protein with
potent transforming capability. The fusion protein
strongly activates the MAPK1 and the PIK3CA/AKT1
pathways [96]. The occurrence of the ETV6-NTRK3
translocation and consequential expression of the
oncogene is an initiating event in the genesis of
secretory breast cancer [97]. The ETV6-NTRK3 trans-
location is demonstrated either by break-apart or by
fusion FISH design. Positive signal patterns have
been seen in most secretory breast carcinoma tumour
cells using either assay strategy.
Chromosomal translocations mainly associated
with colorectal cancer
The first recurrent fusion gene in colorectal cancer
was reported in 2011 [98]. Bass et al correlated the
genomes of nine colorectal cancers with paired non-
neoplastic tissue controls. Recurrent VTI1A-TCF7L2
fusion was identified in 3% of colorectal cancers
[98]. Their findings indicated that functionally impor-
tant fusion events also occur in colorectal cancers,
but the clinical impact of these is yet to be eluci-
dated. RNA-sequencing studies reported by Seshagiri
et al identified multiple fusion transcripts in colo-
rectal cancer, including recurrent gene fusions involv-
ing R-spondin family members EIF3E-RSPO2 and
PTPRK-RSPO3 that occurred with a cumulative fre-
quency of 10% in colorectal cancers [99]. Other
translocations reported in recent years include EML4-
ALK, C2orf44-ALK, SLC34A2-ROS1 and NAV2-
TCF7L1 [66].
Chromosomal translocations mainly associated
with thyroid cancer
More than 10 rearrangements involving RET have been
reported; all of the rearrangements are formed by fusion
of the RET tyrosine kinase domain with a fusion partner
gene [100–103]. RET rearrangements have been identi-
fied almost exclusively in papillary thyroid carcinomas;
most frequent were RET-CCDC6 (60%), RET-NCOA4
(20%) and RET- PRKAR1A (5–12%) [67,68,104]. The
fusion genes code for constitutively activated proteins
driving uncontrolled proliferation of follicular cells.
Kelly et al reported that STRN-ALK fusion occurs
in a subset of patients with highly aggressive types
of thyroid cancer and provide initial evidence sug-
gesting that it may represent a therapeutic target for
20 L Cheng et al
VC 2017 The Authors The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd
J Path: Clin Res 2017
these patients. STRN-ALK fusion protein leads to
constitutive activation of ALK kinase [105].
Follicular thyroid carcinoma accounts for approxi-
mately 20% of all thyroid malignancies. The
t(2;3)(q13;p25) translocation, fusion of the thyroid
transcription factor, paired box gene 8 (PAX8) with
peroxisome proliferator activated receptor c
(PPARG) is most commonly observed (30%) in fol-
licular thyroid carcinoma [106]. The fusion product
acts as an oncogene by accelerating cellular growth,
down-regulating apoptosis, promoting anchorage-
independence, and causing loss of contact inhibition.
It is noteworthy that rearrangement of these genes
has also been identified in benign thyroid adenomas
with a break-apart frequency between 3% and 6%
[107,108].
Chromosomal translocations mainly associated
with salivary gland tumours
Approximately 20% of salivary gland tumours har-
bour chromosomal translocation [109]. There are four
major recurrent translocations in malignant salivary
gland tumours: the MYB-NFIB fusion in adenoid
cystic carcinoma, the CRTC1-MAML2 fusion in
mucoepidermoid carcinoma, the ETV6-NTRK3 fusion
in mammary analogue secretory carcinoma (MASC),
and the EWSR1-ATF1 fusion in hyalinizing clear cell
carcinoma (HCCC) (Table 2) [96,97,110,111]. The
identification of recurrent tumour-specific chromo-
somal translocations and novel fusion oncogenes has
diagnostic, therapeutic, and prognostic implications.
Pleomorphic adenoma
Pleomorphic adenoma is a benign salivary gland
tumour most often arising in the parotid gland. The
tumour presents with a highly specific and recurrent
pattern of chromosome abnormalities in 70% of
cases. There are four cytogenetic categories of pleo-
morphic adenoma. These involve 8q12 (39%),
12q13-15 (8%), other recurring translocations (23%),
and cytogenetically unchanged cases (30%). Of cases
with rearrangements, the 8q12 rearrangement
[t(3;8)(p21;q12)], represents almost half of the diag-
nostic translocations found.
Mucoepidermoid carcinoma
Mucoepidermoid carcinoma represents a distinct type
of polymorphous tumour, containing three cellular
elements in varying proportions: squamous cells,
mucus-secreting cells, and ‘intermediate’ cells. The
CRTC1-MAML2 fusion is present in 55% of mucoe-
pidermoid carcinomas. The fusion oncogene derived
from chromosomal translocation that binds cyclic-
AMP response element protein related transcription
co-factor 1 (CRTC1) with mastermind-like 2 NOTCH
signalling coactivator (MAML2), t(11;19)(q12;p13) is
aetiological for some mucoepidermoid carcinomas.
When present, this marker confers a favourable sur-
vival outcome when compared with fusion-negative
tumours [112].
Adenoid cystic carcinoma
Recurrent t(6;9)(q22–23;p23–24) translocation in
adenoid cystic carcinoma results in a fusion of the
MYB proto-oncogene with transcription factor gene
NFIB [113]. MYB is a leucine zipper transcription fac-
tor at 6q22-24 that participates in the regulation of
cell proliferation, apoptosis, and differentiation [114].
West et al used FISH to investigate MYB translocation
in 37 of these tumours. MYB-NFIB translocation was
present in 49% of adenoid cystic carcinomas but not
in other salivary gland tumours or non-salivary gland
neoplasms [115]. A subset of about 20% of adenoid
cyst carcinomas lacks any detectable MYB gene fusion
[116,117]. The high frequency of this fusion in
adenoid cystic carcinoma indicates that the transcript
may play a developmental role in a significant subset
of these tumours. Therapies directed against MYB-
NFIB transcriptional targets may improve the progno-
sis for this chemoresistant neoplasm.
Mammary analogue secretory carcinoma
MASC is a recently recognized salivary gland tumour
that is histologically, immunohistochemically, and
genetically similar to secretory carcinoma of the
breast [118]. MASC harbours a t(12;15) (p13;q25)
translocation resulting in fusion of an E-twenty-six
family member (ETV6) and the neurotrophic tyrosine
kinase receptor type 3 (NTRK3) gene [119]. Histolog-
ically, conventional MASC displays a lobulated
growth pattern of a tumour composed of microcystic,
tubular, and solid structures. Between epithelial struc-
tures, one finds abundant eosinophilic homogenous
or bubbly secretions. Majewska et al investigated
seven MASC by FISH, and the ETV6-NTRK3 rear-
rangement was identified in six cases [120]. For
FISH analysis, a dual-colour break-apart probe for
the ETV6 gene exhibits a ‘split’ fluorescent signal in
nuclei where the ETV6 gene participates in transloca-
tion. MASC behaves as a low-grade carcinoma with
15–20% recurrence, lymph node metastases in 15–
20% of cases, and occasional mortality [118,121].
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ETV6 FISH is useful to diagnose difficult cases and
to exclude the tumours that morphologically mimic
MASC.
Hyalinizing clear cell carcinoma
HCCC is a recently described minor salivary gland
tumour composed of glycogen-rich clear cells with
hyalinized or myxoid stroma. Gene fusion between
Ewing sarcoma breakpoint region 1 (EWSR1) and the
activating transcription factor 1 (ATF1) gene is a rel-
atively consistent finding in HCCC [122]. However,
EWSR1-ATF1 translocation could also be found in
other types of tumour including angiomatoid fibrous
histiocytoma, angiosarcoma of the parotid gland,
clear cell sarcoma of soft tissue, and clear cell
sarcoma-like tumour from the GI tract [51,123–126].
In one study, the ATF1 gene translocation was found
in 82% of HCCC cases, but in none of the other
tumours in the differential diagnosis [109].
Chromosomal translocations mainly associated
with Spitz nevi and melanoma
The genetic underpinnings of Spitz nevi are poorly
understood, and alterations in melanoma-associated
oncogenes are typically absent. Spitzoid neoplasms
harbour kinase fusions of ROS1 (17%), NTRK1
(16%), ALK (10%), BRAF (5%) and RET (3%) in a
mutually exclusive pattern [127]. The chimeric pro-
teins are constitutively activated, which stimulate
oncogenic signalling and initiate the tumorigenesis.
In a study of 140 spitzoid neoplasms, Wiesner et al
demonstrated that kinase fusions were present in 18
of 30 Spitz nevi (60%) and within 6 of 8 atypical
Spitz tumours (75%). The kinase gene fusions
involved ROS1 (26%, 16/73), ALK (11%, 8/75),
NTRK1 (11%, 8/75), BRAF (5%, 4/75) and RET (3%,
2/75). FISH can be used as an ancillary tool in the
diagnosis of ambiguous melanocyte neoplasms, since
Spitz nevi are benign and do not require wide exci-
sion [127].
Molecular alterations commonly seen in melano-
mas are typically absent from Spitz nevi and Spitz
nevi contain translocations are not usually found in
melanoma [91,128–130]. Translocations involving
BRAF and MET genes have been recently reported in
melanoma patients (Table 2). BRAF fusion genes
characteristically activate the MAPK pathway with
transformation abilities [131,132]. This activation of
the MAPK pathway renders the tumours potentially
sensitive to MEK inhibition.
MET is a high-affinity tyrosine kinase receptor with
functions in angiogenesis, cellular motility, growth and
invasion [133]. Yeh et al analysed 1202 equivocal pig-
mented skin lesions representing spitzoid melanoma,
Spitz nevi, conventional nevi, deep penetrating nevus-
like lesions and blue nevi. The patients’ tumours were
tested by comparative genomic hybridization. MET
translocations were found in six melanocytic tumours
resulting in the following fusion genes: TRIM4-MET,
ZKSCAN1-MET, PPFIBP1-MET LRRFIP1-MET,
EPS15-MET and DCTN1-MET [134]. MET fusion
genes are driven by the promoter of the partner gene
and express MET without control.
Chromosomal translocations mainly associated
with tumours of the central nervous system
The WHO 2016 classification of tumours of the cen-
tral nervous system emphasizes the importance of
molecular classification [135]. More than 10 translo-
cations have been reported in glioblastomas and gene
fusions occur in approximately 30–50% of glioblas-
toma patients (Table 2) [136–139]. PTPRZ1-MET
translocation was detected in 15% of glioblastomas
in independent cohorts, rendering it the most fre-
quently recurring transcript in glioblastoma. Recently,
Bao et al investigated 272 gliomas by RNA seq and
identified 67 in-frame fusion transcripts, including
three recurrent fusion transcripts: FGFR3-TACC3,
RNF213-SLC26A11 and PTPRZ1-MET [139]. Four-
teen other rare fusion transcripts containing sequen-
ces of genes involved in the canonical glioblastoma
signalling pathways were also found.
Co-deletion of 1p/19q has been observed in up to
70% of oligodendrogliomas and 50% of mixed oli-
goastrocytomas [140–143]. Deletions of 1p and 19q
have been associated with prolonged survival in
patients with oligodendrogliomas and mixed oligoas-
trocytomas. Jenkins et al hypothesized that the
majority of 1p and 19q deletions in gliomas were
derived from a translocation t(1;19)(q10;p10), which
has a prevalence of 81% in all 1p/19q deletion cases
[144].
KIAA1549-BRAF translocations are characteristic
of pilocytic astrocytoma [138,145]. The translocation
was found by whole-genome sequencing of 96 pilo-
cytic astrocytomas [145]. These new molecular reve-
lations suggested that BRAF targeted therapy may be
applicable in pilocytic astrocytomas since the major-
ity of tumours harbour KIAA1549-BRAF fusions
(Table 2).
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Ependymoma arises from the ependymal cells of
the brain and spinal cord. Surgery and irradiation are
the major treatments for this disease since chemother-
apy is ineffective in most patients [146]. Parker et al
showed that more than two-thirds of supratentorial
ependymomas contained chromosomal translocations
between avian reticuloendotheliosis viral oncogene
homologue A (RELA) and chromosome 11 open read-
ing frame 95(C11orf95) [147]. The resulting fusion
protein activates NF-jB target genes, transforming the
cells [148]. This finding is significant not only for
understanding the biology of the tumour but also
affords potential for an effective treatment.
Conclusions
Over the past decade, FISH analysis of neoplasms has
become one of the most rapidly growing areas in
genomic medicine and surgical pathology practice. As
more diagnostic and treatment algorithms incorporate
the results of FISH, demand for the technology will
become more widespread. Common FISH-detected
alterations are chromosome deletions, gains, transloca-
tions, amplifications and polysomy. These chromo-
some alterations may have diagnostic and therapeutic
implications for many tumour types. Integrating
genomic testing into cancer treatment decisions poses
many technical challenges, but rapid progress is being
made in overcoming these precision medicine chal-
lenges. Next generation sequencing platforms allow
detection of fusion genes at both the transcriptional
and genomic levels. The rapidly emerging RNA
sequencing (RNA-seq) technology has empowered an
increasing pace of fusion gene identification. RNA-seq
is superior to current molecular test methods in its
capacity to detect gene mutations simultaneously, the
precise mapping of break-point and joint sequences,
and the discovery of cryptic fusions and fusion genes
with unknown partners or with short physical distance
between the fusion partners.
FISH assessment of chromosomal changes is a
continuously evolving technology. Its role in clarify-
ing cancer diagnoses and its contributions to the deci-
sions involved in choice of cancer therapy will
become ever more important to surgical pathologists
and the clinicians and patients they serve.
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